OnCo
companiesCompany

TransThera Sciences

Chinese biotech running the first phase 3 of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs.

Tinengotinib (TT-00420) is a multi-kinase inhibitor potent against FGFR2 kinase-domain resistance mutations; FIRST-308 (phase 3 vs physician's choice chemotherapy in FGFR-altered, FGFRi-refractory cholangiocarcinoma) dosed its first US patient in 2025.

Headquarters
Nanjing, CN
Type
biotech

Products

1top
Phase 3Small-molecule multi-kinase inhibitor (FGFR1-3, VEGFR, Aurora, JAK)
Tinengotinib

A next-generation FGFR inhibitor designed to work after pemigatinib or futibatinib stop working, now in a global phase 3.

Connected

3top

cancers

1
Biliary tract cancer (cholangiocarcinoma)

fronts

1
Targeted Therapy

drugs

1
Phase 3Small-molecule multi-kinase inhibitor (FGFR1-3, VEGFR, Aurora, JAK)
Tinengotinib